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Abstract 
Background: Aberrant expression of miR-193a-3p and astrocyte elevated gene-1 (AEG-1) have been revealed to be 
related to the tumorigenesis of various cancers, including non-small cell lung cancer (NSCLC). However, the signifi-
cance of miR-193a-3p and its correlation with AEG-1 in NSCLC has not been explored. The purpose of this study was 
to evaluate the association between miR-193a-3p and AEG-1 and their relationship with the clinicopathological 
features in NSCLC patients.
Methods: Via online in silico prediction, complementary sequences were found between miR-193a-3p and the 
3′-untranslated region of AEG-1. Three independent cohorts were applied in the current study. Firstly, miR-193a-3p 
level was detected in 125 cases of NSCLC with quantitative real-time PCR (qRT-PCR). Secondly, AEG-1 protein level was 
evaluated in 339 cases of lung cancers with immunohistochemistry. Finally, the relationship between miR-193a-3p 
and AEG-1 protein expression was verified in another group with 65 cases of NSCLC.
Results: The results showed that miR-193a-3p level was decreased in NSCLC tissues and significantly negatively 
related to tumor size (r = −0.277, P = 0.002), clinical TNM stage (r = −0.226, P = 0.011), lymph node metastasis 
(r = −0.186, P = 0.038), epidermal growth factor receptor (EGFR) protein level (r = −0.272, P = 0.041). On the con-
trary, AEG-1 protein expression was up-regulated in NSCLC and positively relative to tumor size (r = 0.240, P < 0.001), 
TNM stages (r = 0.164, P = 0.002) and lymph node metastasis (r = 0.232, P < 0.001) in NSCLC patients. In addition, 
miR-193a-3p was found to be inversely associated with AEG-1 protein expression in the third cohort (r = −0.564, 
P < 0.001).
Conclusion: In conclusion, miR-193a-3p and AEG-1 might be responsible for the carcinogenesis and aggressive-
ness of NSCLC. AEG-1 has the potential to be one of the targeted genes of miR-193a-3p. However, future in vitro and 
in vivo experiments are needed to verify this hypothesis.
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Background
Lung cancer remains to be the leading cause of deaths 
associated with cancer worldwide [1]. Non-small-
cell lung cancer (NSCLC), the predominant subtype, 
accounts for 75–80% of all lung cancer patients [2]. 
Despite advances have been developed in clinical and 
experimental oncology, the overall survival rate of 5 years 
for lung cancer is still unsatisfactory. However, there 
are no specific and sensitive biomarkers for diagnosis 
and prognosis prediction of NSCLC due to the complex 
mechanism underlying this malignancy. Therefore, it is 
urgent to explore the mechanisms and to discover new 
biomarkers for the prevention and prediction of NSCLC 
progression.
MicroRNAs (miRNAs), which are endogenous non-
coding and evolutionarily conserved RNAs of about 
19–24 nucleotides, can act as tumor suppressor genes 
or oncogenes [3]. In recent years, more and more stud-
ies have confirmed that miRNAs can regulate the pro-
cesses of cancer metastasis, invasion, proliferation, 
apoptosis and prognosis [4–8]. MiR-193a is one of 
the miRNAs involved in carcinogenesis, which con-
sists of miR-193a-3p and -5p. Researches have shown 
that miR-193a-3p plays essential roles in the multi-
chemoresistance of bladder cancer through regulating 
PSEN1/HOX9/LOXL4 gene expression [9–11]. Moreo-
ver, decreased expression of miR-193a-3p was found to 
be correlated with metastasis, apoptosis and prolifera-
tion in breast cancer and ovary cancer [12, 13]. To date, 
four studies have reported that miR-193a-3p expression 
decreased in NSCLC tissues and hence, miR-193a-3p 
could be functioned as a tumor suppressor gene [14–17]. 
However, three of aforementioned four studies worked 
on NSCLC cell lines but not clinical samples [14–16], and 
only Yu et al. [17] studied the role of miR-193a-3p with 
human specimens, however, the patient size was small 
with 73 cases.
Astrocyte elevated gene-1 (AEG-1), also recognized as 
MTDH (metadherin) or Lyric (lysine-rich CEACAM1), 
was initially emerged as a HIV-1-inducible gene in 
human fetal astrocytes. Researches have demonstrated 
that AEG-1 contributes to several hallmarks of tumor 
progression, including metastasis, invasion and prolifera-
tion [18]. Furthermore, several studies also verified that 
increased expression of AEG-1 was intensely related to 
the carcinogenesis and progression of NSCLC [19–24]. 
Similar as other genes, AEG-1 can serve as targeted 
gene of several miRNAs, for instance, the correlations 
between miR-30c, -145, -375 and AEG-1 were proved to 
be responsible for the processes of NSCLC [24–26].
Based on the prediction in silico, complementary 
sequences were found between miR-193a-3p and the 
3′-untranslated region of AEG-1. However, to our 
knowledge, no study has been reported on the associa-
tion between miR-193a-3p and AEG-1 in NSCLC. Thus, 
this study was performed to investigate the relationship 
between expression of miR-193-3p and AEG-1 protein, 
as well as their clinical significance for NSCLC in three 
independent cohorts.
Results
Expression and clinicopathological significance 
of miR‑193a‑3p in NSCLC
To measure the expression of miR-193a-3p, we per-
formed qRT-PCR in 125 pairs of NSCLC tissues and 
matched non-tumorous tissues. The expression level of 
miR-193a-3p was 4.5076  ±  2.7700 in NSCLC tissues, 
which was significantly lower than that of normal tissues 
(7.0791  ±  2.9787, P  <  0.001, Table  1; Fig.  1a). Moreo-
ver, as shown in Fig.  1b, the area under the curve from 
ROC of the miR-193a-3p was 0.739 (95% CI 0.678–0.800, 
P  <  0.001). At a cut-off value of 0.4 estimated by the 
median expression of miR-193a-3p in all lung tissues, 
including NSCLC and normal lung, and the sensitivity 
and specificity were 0.3832 and 0.8500, respectively.
The associations between miR-193a-3p and patient 
parameters were summarized in Table 1. Compared with 
those whose tumor size was >3 cm (3.7574 ± 2.4984), the 
expression level of miR-193a-3p was markedly down-
regulated in those with smaller tumor (5.3203 ± 2.8395, 
P = 0.001, Fig. 2a). Decreased expression of miR-193a-3p 
was found in patients with lymph node metastasis 
(4.0381  ±  2.6739) compared with those without lymph 
node metastasis(5.0861  ±  2.8002, P  =  0.035, Fig.  2b). 
Besides, in comparison with NSCLC patients in aggres-
sive stages (III and IV, 3.8845 ± 2.4074), the correspond-
ing expression of miR-193a-3p was higher than those 
in early stages (I and II, 5.3269  ±  3.0154, P  =  0.005, 
Fig. 2c). Moreover, miR-193a-3p expression was remark-
ably decreased in NSCLC patients with high expression 
of epidermal growth factor receptor (EGFR) protein 
(3.1588 ±  1.8426), when compared with those with low 
EGFR protein expression (4.6058  ±  2.4525, P  =  0.034, 
Fig. 2d). To identify whether there existed differences of 
miR-193a-3p expression in different pathological grad-
ing, we performed ANOVA test. As a consequence, sig-
nificant difference was identified among different grades 
in relevant with expression of miR-193a-3p (F =  3.271, 
P  =  0.041, Fig.  2e) and miR-193a-3p expression was 
much lower in grading I (3.0353 ± 1.9371) compared to 
grading II (4.8827 ± 2.7938, P = 0.012). Simultaneously, 
Spearman correlation test was conducted to confirm 
the association of miR-193a-3p expression and clinico-
pathological parameters. Negative correlations were 
found between miR-193a-3p and tumor size (r = −0.277, 
P = 0.002), lymph node metastasis (LNM) (r = −0.186, 
Page 3 of 10Ren et al. Cancer Cell Int  (2015) 15:80 
P = 0.038), TNM (r = −0.226, P = 0.011), EGFR protein 
expression (r = −0.272, P = 0.041). No statistically signif-
icant associations were detected between the expression 
of miR-193a-3p and the following factors: age, gender, 
smoking status, vascular invasion, EGFR mutation, EGFR 
amplification or histological classification (Table 1).
Table 1 The relationship between microRNA-193a and clinicopathological parameters in NSCLC
NSCLC non-small-cell lung cancer, N number, SD standard deviation, TNM tumor node metastasis, EGFR epidermal growth factor receptor.
Pathological grading I vs. II: P = 0.012, I vs. III: P = 0.110, II vs. III: P = 0.379.
a ANOVO test was performed.
Clinicopathological feature N MiRNA‑193a relevant expression (2−ΔCq)
Mean ± SD t P value
Tissue
 NSCLC 125 4.5076 ± 2.7700 −7.068 <0.001
 Adjacent non-cancerous lung 125 7.0791 ± 2.9787
Age (years)
 <60 57 4.3444 ± 2.4196 −0.602 0.549
 ≥60 68 4.6444 ± 3.0439
Gender
 Male 75 4.3977 ± 2.6627 −0.542 0.589
 Female 50 4.6724 ± 2.9433
Smoke
 No 38 4.2087 ± 2.3248 0.461 0.646
 Yes 30 3.9533 ± 2.1905
Tumor size (cm)
 ≤3 60 5.3203 ± 2.8395 3.273 0.001
 >3 65 3.7574 ± 2.4984
Lymph node metastasis
 No 56 5.0861 ± 2.8002 2.133 0.035
 Yes 69 4.0381 ± 2.6739
Vascular invasion
 No 90 4.3372 ± 2.6727 −1.104 0.272
 Yes 35 4.9457 ± 3.0016
TNM
 I–II 54 5.3269 ± 3.0154 2.885 0.005
 III–IV 71 3.8845 ± 2.4074
Pathological grading
 I 17 3.0353 ± 1.9371 F = 3.271a 0.041
 II 78 4.8827 ± 2.7938
 III 30 4.3667 ± 2.8883
Histological classification
 Adenocarcinoma 101 4.4685 ± 2.8159 0.276 0.759
 Squamous carcinoma 23 4.5926 ± 2.6476
 Large cell carcinoma 1 6.5000
EGFR amplification
 No 39 4.4905 ± 2.2605 1.501 0.139
 Yes 18 3.4889 ± 2.5128
EGFR protein expression
 Low 40 4.6058 ± 2.4525 2.181 0.034
 High 17 3.1588 ± 1.8426
EGFR mutation
 Wild type 44 4.1030 ± 2.2729 −0.415 0.680
 Mutation 13 4.4154 ± 2.7501
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Among the 57 patients followed-up, 28 patients had 
low miR-193a-3p expression, and 29 had high expression. 
Univariate analysis of overall survival (OS) showed no 
significant relationship with the expression level of miR-
193a-3p (data not shown, P = 0.614).
Overexpression of AEG‑1 in NSCLC FFPE tissues and its 
correlation with the clinical pathological parameters
To further examine whether the expression of AEG-1 
protein was related to the clinical progression of NSCLC, 
we examined 339 paraffin-embedded NSCLC tissues and 
30 normal lung tissues with immunohistochemical stain-
ing. As shown in Table 2, AEG-1 protein expression was 
detected in 172 of 339 (50.7%) NSCLC, which was sig-
nificantly higher than that of normal lung tissues (23.3%, 
P = 0.004). Immunohistochemical staining of the AEG-1 
protein was shown in Figs. 3, 4. The diagnostic value of 
AEG-1 as a biomarker in lung cancer was analyzed with 
ROC curve. The AUC was 0.637 (95% CI 0.540–0.734, 
P  =  0.013), while the sensitivity and specificity were 
0.507 and 0.767, respectively. Meanwhile, expression of 
AEG-1 protein was remarkably increased in NSCLC with 
larger size (Z = 4.414, P < 0.001), advanced clinical TNM 
stages (Z = 3.019, P = 0.003) and LNM status (Z = 4.274, 
P  <  0.001). Moreover, AEG-1 protein expression was 
upregulated in the following NSCLC subgroups:cinar 
adenocarcinoma (P  =  0.014), papillary adenocarci-
noma (P = 0.002) and broncholoalveolar cell carcinoma 
(P  =  0.001). Besides, the relationships between AEG-1 
expression and clinicopathological features were fur-
ther confirmed by Spearman correlation test. The results 
identified that expression of AEG-1 was positively rela-
tive to tumor size (r  =  0.240, P  <  0.001), TNM stages 
(r = 0.164, P = 0.002) and LNM (r = 0.232, P < 0.001). 
These consequences demonstrated that AEG-1 expres-
sion was significantly correlated with the development of 
NSCLC.
The potential relationship between miR‑193a‑3p 
and AEG‑1
To identify the potential target of miR-193a-3p, miRBase, 
PicTar, TargetScan, Tarbase, miRanda and miRecords 
(http://mirecords.biolead.org/) bioinformatics methods 
were used. AEG-1 had the complementary sequences 
to miR-193a-3p (Fig. 5a). We then detected the levels of 
miR-193a-3p and AEG-1 at the same time in cohort III 
and investigated their correlation. When we divided the 
patients into high miR-193a-3p and low miR-193a-3p 
groups, AEG-1 positive expression accounted for 70% 
in the group with decreased expression of miR-193a-3p 
(Fig.  5b). We further compared the difference of miR-
193a-3p level according to the expression of AEG-1. We 
observed that miR-193a-3p was upregulated in AEG-1 
negative patients (8.4147  ±  2.2795) comparing with 
those with AEG-1 positive expression (3.8200 ± 2.5370, 
P < 0.001, Fig. 5c). Lastly, correlation analysis also dem-
onstrated that level of miR-193a-3p was inversely associ-
ated with the expression of AEG-1 in 65 cases of NSCLC 
(r = −0.564, P < 0.001).
Discussion
MiRNAs are widely confirmed as significant factors 
in regulating the progression of malignant tumors. 
Among all of these miRNAs, down-regulation of miR-
193a-3p was closely relevant to the proliferation, apop-
tosis, metastasis, invasion and prognosis of a certain 
type of cancers, especially in NSCLC. MiR-193a-3p was 
demonstrated to be specifically methylated in NSCLC 
Fig. 1 Expression of miR-193a-3p in adjacent non-cancerous lung and NSCLC tissues. Quantitative real-time PCR was performed to evaluate the 
expression of miR-193a-3p. a The difference of miR-193a-3p expression between adjacent non-cancerous lung and NSCLCC tissues. ***P < 0.001. 
b ROC curve of miR-193a-3p expression to distinguish NSCLC from non-cancerous lung. The area under curve (AUC) of miR-193a-3p was 0.739 
(95% CI 0.678–0.800, P < 0.001), at a cut-off value of 0.4. Error bars represented SD. Significance of difference between two groups was analyzed by 
Student’s t test was performed to calculate the difference between two groups (a and b).
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patients, in contrast, methylation indeed contributed 
to the decreased expression of miR-193a-3p in patients 
with NSCLC [14, 16]. Wang et  al. [16] reported that 
methylation-silencing of miR-193a-3p was in favor of 
promoting proliferation and inhibiting apoptosis through 
repressing of NF-κB and MCL1. MiR-193a-3p methyla-
tion was also found to be more frequent in adenocarci-
nomas, a subtype of NSCLC, while no evidence testified 
the association between miR-193a-3p and worse overall 
survival (OS) or disease free survival (DFS) in patients 
with NSCLC [14]. Moreover, another two reports iden-
tified that miR-193a-3p suppressed the aggressive-
ness of NSCLC by negatively regulating ERBB4 in  vivo 
and in vitro [15, 17]. The study reported by Liang et  al. 
verified that the restoration of miR-193a-3p in NSCLC 
repressed the expression of ERBB4 and promoted apop-
tosis and then inhibited proliferation and invasion [15]. 
Additionally, decreased expression of miR-193a-3p/5p 
was remarkably in relation to the TNM and LNM in 
NSCLC by targeting ERBB4, S6K2, PIK3R3 and mTOR 
Fig. 2 The relationship between miR-193a-3p expression and clinicopathological parameters of NSCLC. a Tumor size, b Lymph node metastasis, c 
clinical TNM stage, d EGFR protein expression, e Pathological grading. *P < 0.05, **P < 0.01, ***P < 0.001. The data was representative of two inde-
pendent experiments. Error bars represent SD. *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t test (a–e).
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[17]. Besides, metastasis is thought to be the main fac-
tor for the mortality of lung cancer patients, which may 
provide novel insights for preventing the aggression of 
NSCLC [27].
In our study, down-regulation of miR-193a-3p was 
confirmed in NSCLC tissues compared with match-
ing normal tissues. The ROC curve also demonstrated 
that miR-193a-3p expression could act as a novel bio-
marker for diagnosis of NSCLC. Furthermore, the results 
identified that overexpression of miR-193a-3p was 
inversely related to the tumor size, which was consist-
ent with the results proved by Wang et al. [16] and Liang 
et  al. [15]. In addition, according to the American Joint 
Committee on Cancer (AJCC) staging system for lung 
cancer, tumor diameter is essential for early stage NSCLC 
[27]. Compared with their corresponding groups, miR-
193a-3p expression was much lower in NSCLC patients 
with lymph node metastasis and advanced TNM stages, 
Table 2 The relationship of AEG1 and other clinicopathological parameters in NSCLC
Pathological grading I vs. II: Z = −0.435, P = 0.664; I vs. III: Z = −0.142, P = 0.889; II vs. III: Z = −0.797, P = 0.426.
NSCLC non-small-cell lung cancer, AEG-1 astrocyte elevated gene-1, TNM tumor node metastasis, LNM lymph node metastasis.
a Kruskal–Wallis H test was performed.
NSCLC Number AEG1 negative (n, %) AEG1 positive (n, %) χ2 P
Tissues −2.875 0.004
 Normal tissues 30 23 (76.7) 7 (23.3)
 NSCLC 339 167 (49.3) 172 (50.7)
Gender −0.969 0.332
 Male 254 129 (50.8) 125 (49.2)
 Female 85 38 (44.7) 47 (55.3)
Age (years) −0.616 0.538
 <60 181 92 (50.8) 89 (49.2)
 ≥60 158 75 (47.5) 83 (52.5)
Tumor size −4.414 <0.001
 >7 44 8 (18.2) 36 (81.8)
 ≤7 295 159 (53.4) 136 (46.1)
TNM −3.019 0.003
 I–II 286 151 (52.8) 135 (47.2)
 III–IV 53 16 (30.2) 37 (69.8)
LNM −4.274 <0.001
 Yes 115 38 (33.0) 77 (67)
 No 224 129 (57.6) 95 (42.4)
Distal metastasis −1.474 0.140
 Absent 323 162 (50.2) 161 (49.8)
 Present 16 5 (31.3) 11 (68.7)
Pathological grading 0.648a 0.723
 I 39 20 (51.3) 19 (48.7)
 II 92 51 (55.4) 41 (44.6)
 III 130 65 (50) 65 (50)
Histology 3.090 0.543
127 59 (46.5) 68 (53.5)
175 92 (52.6) 83 (47.4)
28 12 (42.9) 16 (57.1)
8 3 (37.5) 5 (62.5)
1 1 (100) 0 (0.00)
Adenocarcinoma classification 9.054 0.029
Acinar adenocarcinoma 83 42 (50.6) 41 (49.4) −2.464 0.014
Broncholoalveolar 18 5 (27.8) 13 (72.2) −3.291 0.001
Papillary adenocarcinoma 19 6 (31.6) 13 (68.4) −3.097 0.002
Mucinous carcinoma 7 6 (85.7) 1 (14.3) −0.516 0.719
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in agreement with the previous studies [17]. Also, dereg-
ulation of miR-193a-3p was discovered to be significantly 
associated with EGFR protein expression and pathologi-
cal grading. However, no evidence proved the relation-
ship between expression of miR-193a-3p and OS. Thus, 
our current study might provide more information on 
understanding the inhibition of miR-193a-3p on tumori-
genesis and aggression in NSCLC patients.
Numerous researches confirmed that increased expres-
sion of AEG-1 played crucial roles in the carcinogen-
esis of NSCLC [19–24]. As reported, overexpression of 
AEG-1 could promote NSCLC metastasis and invasion 
and repress apoptosis by activating the PI3K/Akt path-
way and enhancing the level of matrix metalloprotein-
ase-9 (MMP-9) and anti-apoptotic protein Bcl-2 [19, 22, 
23]. In addition, suppression of AEG-1 by UA (Ursolic 
acid)/miR-30a/miR-145 may be able to prevent metasta-
sis and invasion of lung cancer through inhibiting epithe-
lial–mesenchymal transition (EMT) in vitro [20, 21, 24]. 
On the opposite, there was also another study investi-
gating that up-regulation of AEG-1 protein was in favor 
of predicting better OS and suppressing proliferation, 
metastasis [28]. In the current study, when compared 
with the normal lung tissues, AEG-1 protein expression 
was notably increased in NSCLC tissues. There existed 
a positive association between AEG-1 expression and 
tumor size, clinical TNM stages and LNM. Accordant to 
previous studies, the expression of AEG-1 protein could 
accelerate the processes of NSCLC, including tumor cell 
proliferation and metastasis. As reported by Liu et al. [20] 
and Wang et  al. [24], AEG-1 could be repressed by the 
up-regulation of miRNAs in aggressiveness of NSCLC. 
However, no study has demonstrated the correlation 
between expression of miR-193a-3p and AEG-1. In cur-
rent study, it was the first time to find the complementary 
sequences between AEG-1 and miR-193a-3p. Meanwhile, 
increased expression of miR-193a-3p was accompanied 
with the decreased expression of AEG-1 protein. Thus 
miR-193a-3p might have the potential to contribute to 
tumor formation and development by partially targeting 
AEG-1 in patients with NSCLC. However, since in silico 
prediction has an estimated false discovery rate of 60%, 
the relationship between AEG-1 and miR-193a-3p needs 
further investigation.
Conclusion
In conclusion, our current study indicates the down-
expression of miR-193a-3p and overexpression of AEG-1 
Fig. 3 Hematoxylin/eosin and immunohistochemical staining of astrocyte elevated gene-1(AEG-1) in lung adenocarcinoma. Hematoxylin/eosin 
(HE) staining of lung adenocarcinoma tissues with AEG-1 expression (a, ×100; b, ×400) and immunohistochemical staining for AEG-1 in lung 
adenocarcinoma (c, ×100; d, ×400)
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Fig. 4 Hematoxylin/eosin and immunohistochemical staining of astrocyte elevated gene-1(AEG-1) in lung squamous carcinoma. Hematoxylin/
eosin (HE) staining of lung squamous carcinoma tissues with AEG-1 expression (a, ×100; b, ×400) and strong cytoplasmic staining for AEG-1 in lung 
squamous carcinoma (c, ×100; d, ×400).
Fig. 5 AEG-1 is a potential target gene of miR-193a-3p and miR-193a-3p was negatively correlated with AEG-1 in NSCLC. a MiRecords predicted 
two different binding sites with AEG-1 3′-UTR region. b Inverse correlation of AEG-1 protein levels detected by IHC in tissues expressing low and 
high levels of miR-193a-3p. c qRT-PCR of miR-193a-3p expression levels determined in 65 NSCLC individuals with classified into low and high AEG-1 
expression. Error bars represent standard deviation (SD). The statistical analysis was performed using Student’s t test (b, c).
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protein are both involved in the metastasis and progres-
sion of NSCLC. Our findings also suggest that AEG-1 
could have the potential to be a target gene of miR-
193a-3p. Therefore, the miR-193a-3p/AEG-1 interaction 
might provide a newly effective strategy for NSCLC diag-
nosis and therapy. However, new in vitro and in vivo tests 
are required to explore the relationship and mechanism 
of miR-193a-3p with AEG-1.
Methods
This research included three independent cohorts of 
lung cancer patients receiving surgical resection with-
out treatment in the First Affiliated Hospital of Guangxi 
Medical University from January 2010 to February 2014 
(cohortI: n = 125; cohort II: n = 369; cohort III: n = 65). 
Pathological tissues involved in cohort I were randomly 
selected from tumor tissues and their paired nonmalig-
nant NSCLC tissues, aged from 23 to 90  years (mean 
age 61.10  years). Cohort II contained 369 cases includ-
ing 339 cancer tissues (aged from 11 to 84  years; mean 
58.17  years) and 30 normal lung tissues (aged from 19 
to 73  years; mean 54.03  years). The clinicopathological 
information of these two cohorts were independently 
shown in Tables  1 and 2. In cohort III independent 
from cohort I and II, all 65 patients were diagnosed as 
NSCLC. The study was approved by the Ethical Com-
mittee of the First Affiliated Hospital of Guangxi Medi-
cal University, and informed consent was obtained from 
the patients for the usage of the tissues for research. All 
samples were reviewed and diagnosed by two independ-
ent pathologists.
RNA isolation and RNA normalization were performed 
as previously described [29–31]. A combination of miR-
191 and miR-103 was the most stable housekeeping genes 
for detection of miR-193a-3p expression [30, 32]. The 
commercial kits used in our study were TaqMan® Micro-
RNA Assays (4427975, Applied Biosystems, Life Tech-
nologies Grand Island, NY 14072 USA) and TaqMan® 
MicroRNA Reverse Transcription Kit (4366596, Applied 
Biosystems, Life Technologies Grand Island, NY 14072 
USA) in a total volume of 10 µL. Sequence of targeted 
miRNA and reference miRNAs used were as follows: 
miR-193a-3p (Applied Biosystems Cat. No. 4427975-
000492): AACUGGCCUACAAAGUCCCAG; miR-
191 (Applied Biosystems Cat. No. 4427975-002299): 
CAACGGAAUCCCAAAAGCAGCU; miR-103 (Applied 
Biosystems Cat. No. 4427975-000439): AGCAGCAU 
UGUACAGGGCUAUGA. Real-time qPCR to detect 
miRNA relevant level was performed with Applied Bio-
systems PCR (7900). The formula  2−Δcq was applied to 
calculate the expression level of miR-193a-3p.
AEG-1 rabbit multi-clonal antibody was purchased 
from Santa Cruz Biotechnology, Inc, Heidelberg, 
Germany. The positive intensity and positive ratio of 
AEG-1 protein was evaluated by two pathologists with 
no prior knowledge of the clinicopathological outcomes 
of the patients. The scores of immunopositive cells was 
semiquantitatively calculated as follows: firstly, scor-
ing according to staining intensity: negative (0), weak 
(1), moderate (2), strong (3); then, scoring based on the 
proportion of positive stained cells: 0 (0%), 1 (1–25%), 
2 (26–50%), 3 (51–75%), and 4 (76–100%). If the patho-
logical scores of multiplication between staining intensity 
and the percentage of positive cells were over 2, it was 
regarded as immunoreaction positive.
Statistical analysis was carried out by using SPSS 20.0. 
Student’s t test and Chi square tests were applied for 
estimating the difference between two groups. One-way 
analysis of variance (ANOVA) test and Kruskal–Wal-
lis H test were performed to evaluate the correlation 
between three or more groups. Receiver operating char-
acteristic (ROC) curve was used to predict NSCLC and 
non-tumorous tissues by miR-193a-3p expression levels. 
Besides, the Kaplan–Meier method and the log-rank test 
were constructed to evaluate the survival analysis, and 
Spearman correlation was conducted to analyze the cor-
relation of miR-193a-3p and AEG-1 expression level and 
clinicopathological parameters. Value of P  <  0.05 was 
considered statistically significant.
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